icon
沙特阿拉伯王国政府所属的官方政府网站。
icon 周四 25 6月 2026
icon
沙特官方政府网站的域名以下列后缀结尾 gov.sa

沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。

icon
政府网站使用以下协议。 HTTPS 用于加密和安全。

沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。

icon
在数字政府管理局注册,编号:
20250831619
建议

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)

icon 2020-07-04
عنوان الدراسة
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)
داعم الدراسة
AstraZeneca
دواء الدراسة
Ticagrelor
رقم بروتوكول الدراسة
D513BC00001
حالة الدراسة
Ongoing
موقع الدراسة
King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad University Hospital (Al-Khobar), Saud Al-Babtain Cardiac Center (Dammam)
مرحلة الدراسة
3b